Propanc Biopharma (PPCB) slid nearly 20% in premarket Tuesday after plunging 17% in after-hours, erasing part of Monday's 104% surge. The biotech announced a $4 million share sale, pricing 1 million shares at $4 alongside its Nasdaq uplisting. Trading volumes spiked to 33,000x normal levels. Proceeds will fund working capital.